90
Views
4
CrossRef citations to date
0
Altmetric
Research Article

Molecular docking, 3D-QSAR, molecular dynamics, synthesis and anticancer activity of tyrosine kinase 2 (TYK 2) inhibitors

, , &
Pages 462-474 | Received 05 Oct 2018, Accepted 22 Jan 2019, Published online: 30 Apr 2019
 

Abstract

A therapeutic rationale is proposed by selectively targeting tyrosine kinase 2 (TYK 2) to obtain potent TYK 2 inhibitors by molecular modeling studies. In the present study, we have taken tyrosine kinase (TYK 2) inhibitors and carried out molecular docking, 3 D quantitative structure–activity relationship (3D-QSAR) analysis and molecular dynamics (MD). Based on the 3D-QSAR results thirteen new compounds (R-1 to R-13) were designed and synthesized in good yields. The synthesized molecules were evaluated for their in vitro anticancer activity against LnCap and A549 cell lines. The molecules R-1, R-3, R-5, R-7, and R-10 exhibited considerable anti cancer activity.

Acknowledgements

We gratefully acknowledge TriposInc, USA and Schrödinger LLC, New York for providing us the software. We wish to express our gratitude to Department of Chemistry, Osmania University for providing facilities to carry out the research work.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This research was made possible through grants from DST-SERB (SB/EMEQ-004/2013), CSIR (01/(2436)/10/EMR-II), DST-PURSE-II/2017 and UGC/UPE/FAR/OU/2017 New Delhi, India. Dr.Venugopal Akula IICT Hyderabad for mass spectral studies and author’s RI and SB would like to acknowledge financial support from UGC for research fellowships.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.